{
  "slug": "bpc-157",
  "name": "BPC-157",
  "url": "https://aminodesk.com/library/bpc-157",
  "markdown_url": "https://aminodesk.com/library/bpc-157.md",
  "api_url": "https://aminodesk.com/api/v1/compounds/bpc-157",
  "evidence_grade": "C",
  "evidence_grade_detail": "C",
  "legal_status": "2026 policy",
  "legal_status_detail": "compounded on prescription under the October 2026 interim policy. Not FDA-approved.",
  "legal_lane": "interim",
  "goals": [
    "repair"
  ],
  "summary": "The best-known repair peptide, now legally compoundable. Almost all of its evidence is animal work, and an investigation found most of it came from a single lab.",
  "updated": "2026-11-17",
  "clinical_review": "completed 2026-11-14",
  "description": "BPC-157 explained: what it is, how little human research exists, its legal status after the October 2026 HHS policy, the doses people report and where they come from.",
  "facts": [
    {
      "label": "Legal lane",
      "value": "compounded on prescription under the October 2026 interim policy. Not FDA-approved."
    },
    {
      "label": "Evidence grade",
      "value": "C"
    },
    {
      "label": "Forms covered by the policy",
      "value": "BPC-157 acetate as an injection under the skin or into muscle, oral, or topical"
    },
    {
      "label": "Established human dose",
      "value": "none"
    }
  ],
  "sections": [
    {
      "heading": "Overview",
      "markdown": "BPC-157 is the best-known \"healing\" peptide. It can now be compounded on prescription under an interim federal policy, but it is not FDA-approved and has almost no human trial data.\n\n- **Legal lane:** compounded on prescription under the October 2026 interim policy. Not FDA-approved.\n- **Evidence grade:** C\n- **Forms covered by the policy:** BPC-157 acetate as an injection under the skin or into muscle, oral, or topical\n- **Established human dose:** none"
    },
    {
      "heading": "What it is",
      "markdown": "BPC-157 is a synthetic chain of 15 amino acids, based on a fragment of a protein found in stomach fluid. The name stands for \"body protection compound\". It is promoted for tendon, muscle and gut healing."
    },
    {
      "heading": "What the evidence shows",
      "markdown": "Almost all of the research is in rodents, much of it from one laboratory at the University of Zagreb. Those studies report faster healing of tendons, ligaments and gut tissue.\n\nIn people, the published record is three small studies with fewer than 20 participants in total:\n\n- A look back at 12 patients given injections into the knee for pain.\n- A small pilot study in interstitial cystitis, a bladder condition.\n- A 2025 safety pilot in which two healthy adults received 10 mg and then 20 mg by intravenous infusion, with no side effects reported.\n\nThere are no published randomized controlled trials for any use. A Phase 1 trial of an oral form was registered, but no results were published. When FDA scientists reviewed BPC-157 in July 2026, they recommended against allowing it to be compounded; the advisory committee voted 8 to 6 in favor."
    },
    {
      "heading": "Legal status",
      "markdown": "- **September 2023:** the FDA restricted compounding of BPC-157, citing possible immune reactions, impurities and a lack of safety data.\n- **April 2026:** it was removed from the restricted category.\n- **October 30, 2026:** HHS published an interim policy under which state-licensed pharmacies may compound it on an individual prescription.\n\nThe policy is not approval and can be revised. Vials sold online as \"research use only\" are not covered by it. BPC-157 is also prohibited in sport under World Anti-Doping Agency rules."
    },
    {
      "heading": "Reported dosing",
      "markdown": "**No dose has been established in human trials.** Nobody has run the studies that would show how much works, how often, or for how long.\n\nThe figure most often cited by clinics and online is 250 to 500 micrograms a day by injection under the skin. That range is extrapolated from animal studies and from prescriber habit. It did not come from a human dose-finding study.\n\nThe only doses given in a published human safety study were far higher, 10 mg and 20 mg, as single intravenous infusions in a monitored research setting. That study had two participants and was not designed to show a benefit.\n\nIf a clinician prescribes BPC-157, the dose on the prescription is the one to follow. Ask them what it is based on."
    },
    {
      "heading": "Safety",
      "markdown": "- The small human studies did not report serious side effects, but they are far too small to establish safety.\n- Long-term effects in people are unknown.\n- Quality is a separate risk. Products bought outside a pharmacy have no verified contents or sterility."
    },
    {
      "heading": "What it costs",
      "markdown": "Telehealth listings we have seen put a prescribed, compounded supply at roughly $80 to $150 a month. Prices are moving as more providers enter after the October policy."
    },
    {
      "heading": "Common questions",
      "markdown": "### Is BPC-157 legal?\n\nState-licensed pharmacies may compound it on an individual prescription under an interim HHS policy published October 30, 2026. It is not FDA-approved, and vials sold online as research use only are not covered by the policy.\n\n### Does BPC-157 work in humans?\n\nNobody knows yet. Almost all of the research is in rodents. The published human record is three small studies with fewer than 20 participants in total, and there are no randomized controlled trials.\n\n### What is the usual BPC-157 dose?\n\nNo dose has been established in human trials. The figure most often cited, 250 to 500 micrograms a day by injection under the skin, is extrapolated from animal studies and prescriber habit.\n\n### Is BPC-157 banned in sport?\n\nYes. It is prohibited under World Anti-Doping Agency rules.\n\nAdded in the latest update. These answers summarize the sections above; sources are listed below."
    },
    {
      "heading": "Sources",
      "markdown": "- [FDA briefing document: BPC-157-related bulk drug substances (July 2026)](https://www.fda.gov/media/193343/download)\n- [FDA: Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (agenda and briefing documents)](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026)\n- [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)\n- [HHS: 503A peptide enforcement discretion policy (PDF)](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf)\n- [Lee and Burgess, 2025: intravenous safety pilot (PubMed)](https://pubmed.ncbi.nlm.nih.gov/40131143/)\n- [Narrative review of BPC-157 for musculoskeletal healing (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/)\n- [Phase 1 trial registration, NCT02637284](https://clinicaltrials.gov/study/NCT02637284)\n- [GoodRx: FDA developments on peptides](https://www.goodrx.com/health-topic/peptides/what-peptides-are-fda-approved)\n- [Regulatory timeline and committee vote](https://nationwidecompounding.com/bpc-157-compounding-pharmacy-fda-vote/)\n- [BSCG: 2023 safety concerns and anti-doping status](https://www.bscg.org/blogs/single/whats-changing-with-peptide-regulation-in-2026)\n- [Telehealth price listings](https://telehealthally.com/best/best-peptide-telehealth-providers)\n\nThis compound is often sold inside a blend, such as Wolverine or KLOW. A vial holding more than one peptide falls outside the 2026 compounding policy; see [blends and stacks](https://aminodesk.com/stacks).\n\nSee how the two repair peptides differ: [BPC-157 vs TB-500](https://aminodesk.com/compare/bpc-157-vs-tb-500)."
    }
  ],
  "sources": [
    {
      "title": "FDA briefing document: BPC-157-related bulk drug substances (July 2026)",
      "url": "https://www.fda.gov/media/193343/download"
    },
    {
      "title": "FDA: Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (agenda and briefing documents)",
      "url": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026"
    },
    {
      "title": "FDA: Certain bulk drug substances for use in compounding that may present significant safety risks",
      "url": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"
    },
    {
      "title": "HHS: 503A peptide enforcement discretion policy (PDF)",
      "url": "https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf"
    },
    {
      "title": "Lee and Burgess, 2025: intravenous safety pilot (PubMed)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40131143/"
    },
    {
      "title": "Narrative review of BPC-157 for musculoskeletal healing (PMC)",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/"
    },
    {
      "title": "Phase 1 trial registration, NCT02637284",
      "url": "https://clinicaltrials.gov/study/NCT02637284"
    },
    {
      "title": "GoodRx: FDA developments on peptides",
      "url": "https://www.goodrx.com/health-topic/peptides/what-peptides-are-fda-approved"
    },
    {
      "title": "Regulatory timeline and committee vote",
      "url": "https://nationwidecompounding.com/bpc-157-compounding-pharmacy-fda-vote/"
    },
    {
      "title": "BSCG: 2023 safety concerns and anti-doping status",
      "url": "https://www.bscg.org/blogs/single/whats-changing-with-peptide-regulation-in-2026"
    },
    {
      "title": "Telehealth price listings",
      "url": "https://telehealthally.com/best/best-peptide-telehealth-providers"
    }
  ],
  "markdown": "# BPC-157\n\nSource: https://aminodesk.com/library/bpc-157\nPublisher: Amino Desk\nUpdated: 2026-11-17\nClinical review: completed 2026-11-14\n\nBPC-157 is the best-known \"healing\" peptide. It can now be compounded on prescription under an interim federal policy, but it is not FDA-approved and has almost no human trial data.\n\n- **Legal lane:** compounded on prescription under the October 2026 interim policy. Not FDA-approved.\n- **Evidence grade:** C\n- **Forms covered by the policy:** BPC-157 acetate as an injection under the skin or into muscle, oral, or topical\n- **Established human dose:** none\n\n## What it is\n\nBPC-157 is a synthetic chain of 15 amino acids, based on a fragment of a protein found in stomach fluid. The name stands for \"body protection compound\". It is promoted for tendon, muscle and gut healing.\n\n## What the evidence shows\n\nAlmost all of the research is in rodents, much of it from one laboratory at the University of Zagreb. Those studies report faster healing of tendons, ligaments and gut tissue.\n\nIn people, the published record is three small studies with fewer than 20 participants in total:\n\n- A look back at 12 patients given injections into the knee for pain.\n- A small pilot study in interstitial cystitis, a bladder condition.\n- A 2025 safety pilot in which two healthy adults received 10 mg and then 20 mg by intravenous infusion, with no side effects reported.\n\nThere are no published randomized controlled trials for any use. A Phase 1 trial of an oral form was registered, but no results were published. When FDA scientists reviewed BPC-157 in July 2026, they recommended against allowing it to be compounded; the advisory committee voted 8 to 6 in favor.\n\n## Legal status\n\n- **September 2023:** the FDA restricted compounding of BPC-157, citing possible immune reactions, impurities and a lack of safety data.\n- **April 2026:** it was removed from the restricted category.\n- **October 30, 2026:** HHS published an interim policy under which state-licensed pharmacies may compound it on an individual prescription.\n\nThe policy is not approval and can be revised. Vials sold online as \"research use only\" are not covered by it. BPC-157 is also prohibited in sport under World Anti-Doping Agency rules.\n\n## Reported dosing\n\n**No dose has been established in human trials.** Nobody has run the studies that would show how much works, how often, or for how long.\n\nThe figure most often cited by clinics and online is 250 to 500 micrograms a day by injection under the skin. That range is extrapolated from animal studies and from prescriber habit. It did not come from a human dose-finding study.\n\nThe only doses given in a published human safety study were far higher, 10 mg and 20 mg, as single intravenous infusions in a monitored research setting. That study had two participants and was not designed to show a benefit.\n\nIf a clinician prescribes BPC-157, the dose on the prescription is the one to follow. Ask them what it is based on.\n\n## Safety\n\n- The small human studies did not report serious side effects, but they are far too small to establish safety.\n- Long-term effects in people are unknown.\n- Quality is a separate risk. Products bought outside a pharmacy have no verified contents or sterility.\n\n## What it costs\n\nTelehealth listings we have seen put a prescribed, compounded supply at roughly $80 to $150 a month. Prices are moving as more providers enter after the October policy.\n\n## Common questions\n\n### Is BPC-157 legal?\n\nState-licensed pharmacies may compound it on an individual prescription under an interim HHS policy published October 30, 2026. It is not FDA-approved, and vials sold online as research use only are not covered by the policy.\n\n### Does BPC-157 work in humans?\n\nNobody knows yet. Almost all of the research is in rodents. The published human record is three small studies with fewer than 20 participants in total, and there are no randomized controlled trials.\n\n### What is the usual BPC-157 dose?\n\nNo dose has been established in human trials. The figure most often cited, 250 to 500 micrograms a day by injection under the skin, is extrapolated from animal studies and prescriber habit.\n\n### Is BPC-157 banned in sport?\n\nYes. It is prohibited under World Anti-Doping Agency rules.\n\nAdded in the latest update. These answers summarize the sections above; sources are listed below.\n\n## Sources\n\n- [FDA briefing document: BPC-157-related bulk drug substances (July 2026)](https://www.fda.gov/media/193343/download)\n- [FDA: Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (agenda and briefing documents)](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026)\n- [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)\n- [HHS: 503A peptide enforcement discretion policy (PDF)](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf)\n- [Lee and Burgess, 2025: intravenous safety pilot (PubMed)](https://pubmed.ncbi.nlm.nih.gov/40131143/)\n- [Narrative review of BPC-157 for musculoskeletal healing (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/)\n- [Phase 1 trial registration, NCT02637284](https://clinicaltrials.gov/study/NCT02637284)\n- [GoodRx: FDA developments on peptides](https://www.goodrx.com/health-topic/peptides/what-peptides-are-fda-approved)\n- [Regulatory timeline and committee vote](https://nationwidecompounding.com/bpc-157-compounding-pharmacy-fda-vote/)\n- [BSCG: 2023 safety concerns and anti-doping status](https://www.bscg.org/blogs/single/whats-changing-with-peptide-regulation-in-2026)\n- [Telehealth price listings](https://telehealthally.com/best/best-peptide-telehealth-providers)\n\nThis compound is often sold inside a blend, such as Wolverine or KLOW. A vial holding more than one peptide falls outside the 2026 compounding policy; see [blends and stacks](https://aminodesk.com/stacks).\n\nSee how the two repair peptides differ: [BPC-157 vs TB-500](https://aminodesk.com/compare/bpc-157-vs-tb-500).\n\n---\nEducational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.\n",
  "notice": "Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL."
}